Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Moderate to Severe Plaque-type Psoriasis Clear all

Completed Phase 1 Interventional

Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis

NCT02397382

View directory record Official record

Conditions: Psoriasis
Interventions: Guselkumab, Midazolam, Warfarin, Omeprazole, Dextromethorphan, Caffeine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • North Hollywood, California • Orlando, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated Sep 19, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938

View directory record Official record

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: AIN457 150mg, AIN457 300mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 967 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 33
States / cities: Fresno, California • Pasadena, California • Sacramento, California + 28 more

Source: ClinicalTrials.gov public record

Updated May 18, 2015 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578

View directory record Official record

Conditions: Chronic Plaque Psoriasis
Interventions: Placebo, secukinumab (AIN457), etanercept; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more

Source: ClinicalTrials.gov public record

Updated Jan 4, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

NCT01154101

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo, SRT2104; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: St Louis, Missouri • New York, New York • Portland, Oregon + 4 more

Source: ClinicalTrials.gov public record

Updated Oct 12, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299

View directory record Official record

Conditions: Psoriasis, Psoriatic Arthritis
Interventions: Apremilast, Etanercept, Placebo tablet, Placebo injection; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 31
States / cities: Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more

Source: ClinicalTrials.gov public record

Updated Mar 14, 2022 · Synced May 21, 2026, 7:59 PM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

NCT02502188

View directory record Official record

Conditions: Parapsoriasis, Healthy Volunteers
Interventions: CC-90005, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Nov 17, 2019 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

NCT01483599

View directory record Official record

Conditions: Psoriasis
Interventions: CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo; Drug
Lead sponsor: Janssen Inc.; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 18
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more

Source: ClinicalTrials.gov public record

Updated Aug 1, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)

NCT00773734

View directory record Official record

Conditions: Psoriasis, Plaque-type Psoriasis
Interventions: Apremilast 10mg, Apremilast 20mg, Apremilast 30 mg, Placebo, Apremilast 30mg; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older

Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 20
States / cities: Fresno, California • Los Angeles, California • Redwood City, California + 16 more

Source: ClinicalTrials.gov public record

Updated May 6, 2020 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

NCT02207244

View directory record Official record

Conditions: Psoriasis
Interventions: Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 29 more

Source: ClinicalTrials.gov public record

Updated Jul 21, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

NCT03090100

View directory record Official record

Conditions: Psoriasis
Interventions: Guselkumab, Placebo, Secukinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 1,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Oceanside, California + 38 more

Source: ClinicalTrials.gov public record

Updated Sep 30, 2019 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

NCT03504852

View directory record Official record

Conditions: Moderate to Severe Chronic Plaque-type Psoriasis
Interventions: secukinumab 150 mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more

Source: ClinicalTrials.gov public record

Updated Oct 10, 2021 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

NCT01555125

View directory record Official record

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more

Source: ClinicalTrials.gov public record

Updated Aug 7, 2018 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis

NCT01412944

View directory record Official record

Conditions: Plaque-type Psoriasis
Interventions: secukinumab 150mg, secukinumab 10mg/kg i.v. regimen; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Jacksonville, Florida • West Palm Beach, Florida • Boston, Massachusetts + 3 more

Source: ClinicalTrials.gov public record

Updated Mar 17, 2015 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

NCT02016105

View directory record Official record

Conditions: Plaque Type Psoriasis
Interventions: GP2017 Adalimumab, Humira ® Adalimumab; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older

Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 69
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more

Source: ClinicalTrials.gov public record

Updated May 29, 2017 · Synced May 21, 2026, 7:59 PM EDT

Withdrawn Phase 4 Interventional

Trial of an Injectable Biologic and U0279 as Combination Therapy for Severe Plaque-Type Psoriasis

NCT00832364

View directory record Official record

Conditions: Plaque Psoriasis
Interventions: Acitretin (also called U0279), Placebo, Etanercept; Drug · Biological
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Francisco, California • Louisville, Kentucky • New York, New York

Source: ClinicalTrials.gov public record

Updated Apr 20, 2015 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032

View directory record Official record

Conditions: Psoriasis
Interventions: Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years

Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more

Source: ClinicalTrials.gov public record

Updated Sep 11, 2017 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

NCT00267969

View directory record Official record

Conditions: Psoriasis
Interventions: ustekinumab, placebo; Drug
Lead sponsor: Centocor Research & Development, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 28
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more

Source: ClinicalTrials.gov public record

Updated Jun 16, 2013 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

NCT02622386

View directory record Official record

Conditions: Psoriasis
Interventions: Riboflavin, Placebo; Drug · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older

Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Source: ClinicalTrials.gov public record

Updated Jul 27, 2022 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

NCT01490632

View directory record Official record

Conditions: Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
Interventions: Placebo, Baricitinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older

Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more

Source: ClinicalTrials.gov public record

Updated Sep 26, 2019 · Synced May 21, 2026, 7:59 PM EDT

Completed Not applicable Interventional Accepts healthy volunteers Results available

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

NCT00800982

View directory record Official record

Conditions: Psoriasis
Interventions: Narrow band (310-312 nm) ultraviolet light B phototherapy, etanercept; Procedure · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older

Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Source: ClinicalTrials.gov public record

Updated May 6, 2013 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02905331

View directory record Official record

Conditions: Psoriasis
Interventions: Guselkumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older

Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 8
States / cities: Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more

Source: ClinicalTrials.gov public record

Updated Feb 3, 2025 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

NCT00941031

View directory record Official record

Conditions: Chronic Plaque-type Psoriasis
Interventions: AIN457, AIN457A, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more

Source: ClinicalTrials.gov public record

Updated Aug 19, 2015 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301

View directory record Official record

Conditions: Psoriasis
Interventions: XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older

Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more

Source: ClinicalTrials.gov public record

Updated Apr 11, 2022 · Synced May 21, 2026, 7:59 PM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

NCT03724292

View directory record Official record

Conditions: Psoriasis
Interventions: Placebo, VTP-43742; Drug
Lead sponsor: Vitae Pharmaceuticals Inc., an Allergan affiliate; Industry
Eligibility: 18 Years to 45 Years

Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Source: ClinicalTrials.gov public record

Updated Oct 29, 2018 · Synced May 21, 2026, 7:59 PM EDT